CN1198654C - 药用复合物 - Google Patents

药用复合物 Download PDF

Info

Publication number
CN1198654C
CN1198654C CNB008097127A CN00809712A CN1198654C CN 1198654 C CN1198654 C CN 1198654C CN B008097127 A CNB008097127 A CN B008097127A CN 00809712 A CN00809712 A CN 00809712A CN 1198654 C CN1198654 C CN 1198654C
Authority
CN
China
Prior art keywords
preparation
complex
eletriptan
described preparation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008097127A
Other languages
English (en)
Chinese (zh)
Other versions
CN1359303A (zh
Inventor
安妮·比洛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1359303A publication Critical patent/CN1359303A/zh
Application granted granted Critical
Publication of CN1198654C publication Critical patent/CN1198654C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB008097127A 1999-06-29 2000-06-02 药用复合物 Expired - Fee Related CN1198654C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9915231.6 1999-06-29
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex

Publications (2)

Publication Number Publication Date
CN1359303A CN1359303A (zh) 2002-07-17
CN1198654C true CN1198654C (zh) 2005-04-27

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008097127A Expired - Fee Related CN1198654C (zh) 1999-06-29 2000-06-02 药用复合物

Country Status (44)

Country Link
US (2) US6713461B1 (hu)
EP (1) EP1189640B1 (hu)
JP (2) JP4454900B2 (hu)
KR (1) KR20020015067A (hu)
CN (1) CN1198654C (hu)
AP (1) AP2001002369A0 (hu)
AR (1) AR033337A1 (hu)
AT (1) ATE290884T1 (hu)
AU (1) AU770169B2 (hu)
BG (1) BG106151A (hu)
BR (1) BR0011845A (hu)
CA (1) CA2376847C (hu)
CO (1) CO5170494A1 (hu)
CZ (1) CZ20014572A3 (hu)
DE (1) DE60018744T2 (hu)
DZ (1) DZ3320A1 (hu)
EA (1) EA003908B1 (hu)
EC (1) ECSP003551A (hu)
EE (1) EE200100697A (hu)
ES (1) ES2235879T3 (hu)
GB (1) GB9915231D0 (hu)
GE (1) GEP20043377B (hu)
GT (1) GT200000102A (hu)
HR (1) HRP20010951A2 (hu)
HU (1) HUP0201629A3 (hu)
IL (1) IL146341A0 (hu)
IS (1) IS6163A (hu)
MA (1) MA26801A1 (hu)
MX (1) MXPA01013274A (hu)
NO (1) NO20016430L (hu)
NZ (1) NZ515235A (hu)
OA (1) OA11964A (hu)
PA (1) PA8496801A1 (hu)
PE (1) PE20010346A1 (hu)
PL (1) PL352902A1 (hu)
SK (1) SK18932001A3 (hu)
SV (1) SV2002000112A (hu)
TN (1) TNSN00142A1 (hu)
TR (1) TR200103827T2 (hu)
UA (1) UA66932C2 (hu)
UY (1) UY26224A1 (hu)
WO (1) WO2001000243A1 (hu)
YU (1) YU87501A (hu)
ZA (1) ZA200110454B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
WO2019143925A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU212730B (en) 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
AU651637B2 (en) 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
US5665767A (en) 1993-03-05 1997-09-09 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
EP1024833A1 (en) 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
WO1999001135A1 (en) 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
AU770169B2 (en) 2004-02-12
AP2001002369A0 (en) 2001-12-31
SV2002000112A (es) 2002-02-05
IS6163A (is) 2001-11-16
NO20016430L (no) 2002-02-26
DE60018744D1 (de) 2005-04-21
CZ20014572A3 (cs) 2002-08-14
BG106151A (en) 2002-05-31
AR033337A1 (es) 2003-12-17
EA200101106A1 (ru) 2002-06-27
DZ3320A1 (fr) 2001-01-04
JP2003503364A (ja) 2003-01-28
PL352902A1 (en) 2003-09-22
US20040186076A1 (en) 2004-09-23
JP2006257091A (ja) 2006-09-28
NZ515235A (en) 2003-08-29
PE20010346A1 (es) 2001-03-26
IL146341A0 (en) 2002-07-25
EA003908B1 (ru) 2003-10-30
EP1189640B1 (en) 2005-03-16
ATE290884T1 (de) 2005-04-15
PA8496801A1 (es) 2002-02-21
KR20020015067A (ko) 2002-02-27
OA11964A (en) 2006-04-17
HRP20010951A2 (en) 2005-04-30
CA2376847A1 (en) 2001-01-04
MXPA01013274A (es) 2002-06-04
DE60018744T2 (de) 2006-05-18
EP1189640A1 (en) 2002-03-27
CN1359303A (zh) 2002-07-17
UY26224A1 (es) 2001-01-31
AU4774100A (en) 2001-01-31
UA66932C2 (en) 2004-06-15
GB9915231D0 (en) 1999-09-01
YU87501A (sh) 2004-05-12
HUP0201629A3 (en) 2003-11-28
ECSP003551A (es) 2002-01-25
TNSN00142A1 (fr) 2005-11-10
SK18932001A3 (sk) 2002-09-10
WO2001000243A1 (en) 2001-01-04
TR200103827T2 (tr) 2002-05-21
NO20016430D0 (no) 2001-12-28
ES2235879T3 (es) 2005-07-16
US6713461B1 (en) 2004-03-30
BR0011845A (pt) 2002-03-05
JP4454900B2 (ja) 2010-04-21
EE200100697A (et) 2003-02-17
MA26801A1 (fr) 2004-12-20
CA2376847C (en) 2007-09-25
ZA200110454B (en) 2002-12-20
CO5170494A1 (es) 2002-06-27
GT200000102A (es) 2001-12-14
GEP20043377B (en) 2004-04-13
HUP0201629A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
CN1025150C (zh) 能延续释放的新药物制剂的制备方法
CA2345121C (en) Pharmaceutical composition for the treatment of acute disorders
ES2205000T5 (es) Composición farmacéutica que contiene irbesartán
CN1142783C (zh) 用于治疗高危葡萄糖耐量降低的药剂
CN1112921C (zh) 含微粉化奈必洛尔的组合物
HU230421B1 (hu) Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek
CN1942177A (zh) 醋酸巴泽多昔芬固体分散剂型
CN1165649A (zh) 增加睾酮的方法
JP3518601B2 (ja) エバスタイムまたはその類似体に基づく医薬組成物
CN1864672A (zh) 一种盐酸氨溴索固体分散体及其组合物
CN1198654C (zh) 药用复合物
CN1610539A (zh) 含有5ht1受体激动剂的药物组合物
CN1882321A (zh) 包含盐酸文拉法辛的小丸
CN1226175A (zh) 吸收促进剂
JP2003512330A (ja) シクレソニド含有水性医薬組成物
CN1682739A (zh) 头孢羟氨苄干混悬及制备方法
CN115124532B (zh) 大黄酸与苦参碱共晶物及制备方法和其组合物与用途
CN1903351A (zh) 妇宁凝胶剂及其制备方法
CN100341495C (zh) 格列本脲固体分散体、口服组合物及其制备方法
CN1744917A (zh) 经肺给药用缓释性制剂学组合物
CN1878538A (zh) 用于治疗肥胖的mtp抑制剂的固体无定形分散体
CN1868477A (zh) 一种盐酸雷诺嗪制剂配方
RU2260424C9 (ru) Новая композиция для перорального введения
WO2008064595A1 (fr) 5-[(2r)-[2-[2-[2-(2,2,2-trifluoroéthoxy)phénoxy]éthyl]amino]propyl]-2-méthoxybenzenesulfonamide
BG1677U1 (bg) Фармацевтичен състав със стабилни частици на солифенацин или негова сол

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044713

Country of ref document: HK